T-cell populations in the blood of recipients with cGvHD, no GvHD, and TCD BM
| Cell type . | Days after MCMV infection . | |||||
|---|---|---|---|---|---|---|
| cGVHD . | No cGVHD . | TCD BM . | ||||
| 0 . | 10 . | 0 . | 10 . | 0 . | 10 . | |
| T cells* | ||||||
| Donor spleen | ||||||
| CD8 | 0.1 ± 0.2 | 12.4 ± 0.1‡ | 0.1 ± 0.01 | 2.8 ± 1.6‡ | — | — |
| CD4 | 0.03 ± 0.0 | 0.2 ± 0.1 | 0.01 ± 0.02 | 0.3 ± 0.02 | — | — |
| Donor BM | ||||||
| CD8 | 0.3 ± 0.1 | 1.7 ± 0.8‡ | 0.3 ± 0.1 | 2.7 ± 1.4‡ | 0.2 ± 0.1 | 4.2 ± 2.1‡ |
| CD4 | 0.5 ± 0.2 | 0.7 ± 0.3 | 0.7 ± 0.2 | 0.6 ± 0.2 | 0.5 ± 0.2 | 0.7 ± 0.1 |
| Host | ||||||
| CD8 | 0.003 ± 0.004 | 0.03 ± 0.02 | 0.05 ± 0.04 | 0.3 ± 0.4 | 0.08 ± 0.05 | 0.7 ± 0.3 |
| CD4 | 0.002 ± 0.003 | 0.01 ± 0.003 | 0.08 ± 0.07 | 0.06 ± 0.05 | 0.1 ± 0.07 | 0.1 ± 0.03 |
| MCMV tetramer-positive CD8+ T cells† | ||||||
| Donor spleen | 0.1 ± 0.2 | 38.6 ± 33.1§ | 0.3 ± 0.4 | 9.3 ± 5.5§ | ||
| Donor BM | < 0.1 | 13.6 ± 8.5§ | < 0.1 | 32.1 ± 9.2§ | 9.6 ± 7.3 | 50.7 ± 28.5§ |
| Host | < 0.1 | 6.2 ± 6.2 | < 0.1 | 11.3 ± 4.5§ | < 0.1 | 9.8 ± 6.0§ |
| Cell type . | Days after MCMV infection . | |||||
|---|---|---|---|---|---|---|
| cGVHD . | No cGVHD . | TCD BM . | ||||
| 0 . | 10 . | 0 . | 10 . | 0 . | 10 . | |
| T cells* | ||||||
| Donor spleen | ||||||
| CD8 | 0.1 ± 0.2 | 12.4 ± 0.1‡ | 0.1 ± 0.01 | 2.8 ± 1.6‡ | — | — |
| CD4 | 0.03 ± 0.0 | 0.2 ± 0.1 | 0.01 ± 0.02 | 0.3 ± 0.02 | — | — |
| Donor BM | ||||||
| CD8 | 0.3 ± 0.1 | 1.7 ± 0.8‡ | 0.3 ± 0.1 | 2.7 ± 1.4‡ | 0.2 ± 0.1 | 4.2 ± 2.1‡ |
| CD4 | 0.5 ± 0.2 | 0.7 ± 0.3 | 0.7 ± 0.2 | 0.6 ± 0.2 | 0.5 ± 0.2 | 0.7 ± 0.1 |
| Host | ||||||
| CD8 | 0.003 ± 0.004 | 0.03 ± 0.02 | 0.05 ± 0.04 | 0.3 ± 0.4 | 0.08 ± 0.05 | 0.7 ± 0.3 |
| CD4 | 0.002 ± 0.003 | 0.01 ± 0.003 | 0.08 ± 0.07 | 0.06 ± 0.05 | 0.1 ± 0.07 | 0.1 ± 0.03 |
| MCMV tetramer-positive CD8+ T cells† | ||||||
| Donor spleen | 0.1 ± 0.2 | 38.6 ± 33.1§ | 0.3 ± 0.4 | 9.3 ± 5.5§ | ||
| Donor BM | < 0.1 | 13.6 ± 8.5§ | < 0.1 | 32.1 ± 9.2§ | 9.6 ± 7.3 | 50.7 ± 28.5§ |
| Host | < 0.1 | 6.2 ± 6.2 | < 0.1 | 11.3 ± 4.5§ | < 0.1 | 9.8 ± 6.0§ |
— indicates not applicable.
Recipients of untreated DLI (cGvHD), amotosalen-treated (no GvHD), and TCD BM (TCD BM only) were bled on 133 days after transplantation (day 0), infected with 2.5 × 104 PFUs MCMV, and bled on day 10 after infection. The CD4+ and CD8+ T cells (× 106) per mL of blood were measured by FACS analysis.
The absolute number of MCMV peptide-specific tetramer-positive CD8+ T cells (× 103) per mL of blood was measured by FACS analysis.
P < .05 (Student t test) compared with uninfected condition. Four to 5 mice were used per group. The data represent 1 of 2 similar experiments.
P < .05 (Student t test) compared with the uninfected conditions.